Seaport Therapeutics, Inc.

seaporttx.com

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company, which engages in the provision of inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company is headquartered in Boston, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2026-05-01. The firm is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. The company is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD.